Credit Suisse’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.18M | Buy |
74,728
+1,853
| +3% | +$56.9K | ﹤0.01% | 1788 |
|
|
2023
Q4 | $2.46M | Buy |
72,875
+19,481
| +36% | +$570K | ﹤0.01% | 1762 |
|
|
2023
Q3 | $1.64M | Sell |
53,394
-2,455
| -4% | -$88.5K | ﹤0.01% | 1955 |
|
|
2023
Q2 | $2.24M | Buy |
55,849
+675
| +1% | +$27.9K | ﹤0.01% | 1834 |
|
|
2023
Q1 | $2.25M | Buy |
55,174
+1,019
| +2% | +$40.5K | ﹤0.01% | 1787 |
|
|
2022
Q4 | $2.09M | Buy |
54,155
+7,095
| +15% | +$345K | ﹤0.01% | 1842 |
|
|
2022
Q3 | $2.5M | Buy |
47,060
+1,678
| +4% | +$93.3K | ﹤0.01% | 1697 |
|
|
2022
Q2 | $2.65M | Sell |
45,382
-6,091
| -12% | -$399K | ﹤0.01% | 1716 |
|
|
2022
Q1 | $3.93M | Buy |
51,473
+6,750
| +15% | +$450K | ﹤0.01% | 1634 |
|
|
2021
Q4 | $2.69M | Sell |
44,723
-19,965
| -31% | -$1.1M | ﹤0.01% | 2551 |
|
|
2021
Q3 | $3.62M | Buy |
64,688
+13,044
| +25% | +$752K | ﹤0.01% | 2321 |
|
|
2021
Q2 | $3.13M | Buy |
51,644
+4,661
| +10% | +$295K | ﹤0.01% | 2483 |
|
|
2021
Q1 | $3.29M | Sell |
46,983
-20,993
| -31% | -$1.5M | ﹤0.01% | 2436 |
|
|
2020
Q4 | $4.07M | Buy |
67,976
+28,009
| +70% | +$1.64M | ﹤0.01% | 2270 |
|
|
2020
Q3 | $2.4M | Sell |
39,967
-33,392
| -46% | -$1.94M | ﹤0.01% | 2286 |
|
|
2020
Q2 | $3.85M | Sell |
73,359
-17,670
| -19% | -$738K | ﹤0.01% | 1885 |
|
|
2020
Q1 | $3.05M | Sell |
91,029
-7,458
| -8% | -$310K | ﹤0.01% | 1833 |
|
|
2019
Q4 | $4.46M | Buy |
98,487
+63,626
| +183% | +$2.7M | ﹤0.01% | 1963 |
|
|
2019
Q3 | $1.33M | Sell |
34,861
-42,281
| -55% | -$1.69M | ﹤0.01% | 2796 |
|
|
2019
Q2 | $3.35M | Sell |
77,142
-55,375
| -42% | -$2.35M | ﹤0.01% | 2069 |
|
|
2019
Q1 | $5.04M | Buy |
132,517
+95,778
| +261% | +$3.74M | ﹤0.01% | 1704 |
|
|
2018
Q4 | $1.58M | Sell |
36,739
-312
| -0.8% | -$14.6K | ﹤0.01% | 2418 |
|
|
2018
Q3 | $1.82M | Sell |
37,051
-4,390
| -11% | -$190K | ﹤0.01% | 2413 |
|
|
2018
Q2 | $1.33M | Sell |
41,441
-3,457
| -8% | -$119K | ﹤0.01% | 2793 |
|
|
2018
Q1 | $1.4M | Sell |
44,898
-28,975
| -39% | -$1.03M | ﹤0.01% | 2714 |
|
|
2017
Q4 | $3.37M | Buy |
73,873
+30,310
| +70% | +$1.2M | ﹤0.01% | 2049 |
|
|
2017
Q3 | $1.64M | Buy |
43,563
+18,874
| +76% | +$759K | ﹤0.01% | 2719 |
|
|
2017
Q2 | $1.18M | Buy |
24,689
+2,311
| +10% | +$107K | ﹤0.01% | 2599 |
|
|
2017
Q1 | $1.02M | Sell |
22,378
-114,108
| -84% | -$4.93M | ﹤0.01% | 2850 |
|
|
2016
Q4 | $4.41M | Buy |
136,486
+71,417
| +110% | +$2.38M | ﹤0.01% | 1744 |
|
|
2016
Q3 | $2.23M | Sell |
65,069
-22,925
| -26% | -$898K | ﹤0.01% | 2293 |
|
|
2016
Q2 | $2.97M | Buy |
87,994
+57,788
| +191% | +$2.84M | ﹤0.01% | 2033 |
|
|
2016
Q1 | $1.6M | Sell |
30,206
-20,527
| -40% | -$1.2M | ﹤0.01% | 2375 |
|
|
2015
Q4 | $3.9M | Buy |
50,733
+11,305
| +29% | +$640K | ﹤0.01% | 1786 |
|
|
2015
Q3 | $1.62M | Sell |
39,428
-23,522
| -37% | -$1.44M | ﹤0.01% | 2409 |
|
|
2015
Q2 | $4.45M | Buy |
62,950
+33,031
| +110% | +$2.6M | ﹤0.01% | 1851 |
|
|
2015
Q1 | $2.66M | Sell |
29,919
-19,459
| -39% | -$1.97M | ﹤0.01% | 2158 |
|
|
2014
Q4 | $4.38M | Buy |
49,378
+15,482
| +46% | +$1.46M | ﹤0.01% | 1867 |
|
|
2014
Q3 | $3.29M | Buy |
33,896
+1,318
| +4% | +$128K | ﹤0.01% | 2088 |
|
|
2014
Q2 | $2.99M | Buy |
32,578
+8,984
| +38% | +$684K | ﹤0.01% | 2378 |
|
|
2014
Q1 | $1.65M | Sell |
23,594
-39,689
| -63% | -$2.7M | ﹤0.01% | 2670 |
|
|
2013
Q4 | $3.64M | Buy |
63,283
+31,303
| +98% | +$1.65M | ﹤0.01% | 2106 |
|
|
2013
Q3 | $1.54M | Buy |
31,980
+7,619
| +31% | +$278K | ﹤0.01% | 2622 |
|
|
2013
Q2 | $706K | Buy |
+24,361
| New | +$705K | ﹤0.01% | 3064 |
|
Other funds holding PCRX
FCM
SIMG
Credit Suisse's PCRX Position: Q1 2024 in Review
Credit Suisse increased its Pacira BioSciences (PCRX) stake by 2.5% in Q1 2024, buying an estimated $56.9K and bringing the position to 74,728 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1788.
Credit Suisse first reported a position in PCRX in Q2 2013 and has held it in 44 quarters since. The position peaked at $5.04M in Q1 2019. 271 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.
- Credit Suisse held 74,728 shares of Pacira BioSciences worth $2.18M as of Q1 2024.
- Credit Suisse bought 1,853 Pacira BioSciences shares in Q1 2024, an estimated $56.9K.
- Pacira BioSciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1788 holding.
- Credit Suisse first reported a position in Pacira BioSciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Pacira BioSciences position peaked at $5.04M in Q1 2019.
- 271 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.